ACCESS Newswire

Blue Lagoon Resources Inc.

15.7.2021 19:22:16 CEST | ACCESS Newswire | Press release

Share
Blue Lagoon Completes $8.13 Million Private Placement Lead by a Strategic Investment by Crescat Capital for $1.5 Million

STRONG MARKET DEMAND LEADS TO 48% OVER SUBSCRIPTION

VANCOUVER, BC / ACCESSWIRE / July 15, 2021 / Blue Lagoon Resources Inc. (the "Company") (CSE:BLLG) (FSE:7BL) (OTCQB:BLAGF)is pleased to announce that further to its news release dated July 8, 2021, the Company has closed a non-brokered flow through and non-flow through financing for proceeds of $8,130,908.31. Crescat Capital LLC ("Crescat") was the lead order and made a strategic investment of $1.5 Million, representing more than 18% of the total financing. In addition, Crescat requested and secured, participation rights that provide for an option to participate in all future financings.

"We are very pleased with the strong market demand that came from sophisticated investors whose desire to participate in our company lead to a strong closing of this financing which was 48% over subscribed," said Rana Vig, President & CEO of Blue Lagoon Resources. "With this capital raise, an existing healthy treasury, no debt, and nearly $4 million in-the-money warrants, the Company will be very well funded to execute on an aggressive drill program at Dome Mountain this year, one that could result in the recognition of Dome Mountain as a potentially large, high-grade gold system," he added.

FINANCING DETAILS

The private placement (the "Private Placement") consisted of 4,761,154 charity flow-through units ("Charity Units") at a price of $0. 7425 per Unit, 609,758 regular flow-through units (the "FT Units") at a price of $0.82 per unit, and 7,446,818 non-flow-through units (the "NFT Units") at a price of $0.55 per unit, for aggregate gross proceeds to the Company of $8,130,908.31. Each of the units is comprised of one common share of the Company and one-half of one common share purchase warrant. Each whole warrant is exercisable into one common share of the Company at an exercise price of $0.75 per share in the case of the Charity Units and the NFT Units, or $1.10 per share in the case of the FT Units, until July 15, 2023.

Proceeds from the sale of the Charity Units and FT Units will be used for exploration activities in accordance with flow-through tax rules. Proceeds from the sale of the NFT Units will be used for exploration as well as for general working capital purposes.

The Company paid finders' fees in cash in the aggregate amount of $171,863.08, equal to 7% of the gross proceeds from the sale of Units to certain third parties sourced by the finders and issued an aggregate of 202,199 finders' warrants to purchase that number of common shares of the Company, equal to 7% of the number of Units sold to those third parties. The finder's warrants may be exercised to acquire common shares of the Company at a price of $0.75 per common share until July 15, 2023 and are otherwise on the same terms as the Private Placement warrants. 42,683 finder's warrants are exercisable at a price of $1.10 per common share until July 15, 2023.

The securities issued pursuant to the Private Placement are subject to a statutory four month hold period ending on November 16, 2021 in accordance with applicable securities laws.

OPTION GRANT

The Company has granted a total of 960,000 stock options to directors, employees, and consultants of the Company in accordance with the Company's stock option plan. Each option is exercisable into one common share of the Company at a price of $0.70 per share. The options vested on grant and will expire on July 15, 2026. The stock options are subject to the acceptance of the Canadian Securities Exchange (CSE).

About Crescat Capital LLC

Crescat is a global macro asset management firm headquartered in Denver, Colorado. Crescat's mission is to grow and protect wealth over the long term by deploying tactical investment themes based on proprietary value-driven equity and macro models. Crescat's goal is industry leading absolute and risk-adjusted returns over complete business cycles with low correlation to common benchmarks. Crescat's investment process involves a mix of asset classes and strategies to assist with each client's unique needs and objectives and includes Global Macro, Long/Short, Large Cap and Precious Metals funds.

Crescat is advised by its technical consultant Dr. Quinton Hennigh on investments in gold and silver resource companies. Dr. Hennigh became an economic geologist after obtaining his PhD in Geology/Geochemistry from the Colorado School of Mines. He has more than 30 years of exploration experience with major gold mining firms that include Homestake Mining, Newcrest Mining and Newmont Mining. Recently, Dr. Hennigh founded Novo Resources Corp (TSXV: NVO) and serving as Chairman. Among his notable project involvements are First Mining Gold's Springpole gold deposit in Ontario, Kirkland Lake Gold's acquisition of the Fosterville gold mine in Australia, the Rattlesnake Hills gold deposit in Wyoming, and Lion One's Tuvatu gold project on Fiji, among many others.

For further information, please contact:

Rana Vig
President and Chief Executive Officer Telephone: 604-218-4766
Email: rana@ranavig.com

The CSE has not reviewed and does not accept responsibility for the adequacyor accuracy of this release. The securities referenced in this news release have not and will not be registered under the U.S. Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This news release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that Blue Lagoon Resources Inc. (the "Company") expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include use of proceeds from the Private Placement and acceptance of the stock options by the CSE. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE: Blue Lagoon Resources Inc.



View source version on accesswire.com:
https://www.accesswire.com/655718/Blue-Lagoon-Completes-813-Million-Private-Placement-Lead-by-a-Strategic-Investment-by-Crescat-Capital-for-15-Million

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye